Compare PRA & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | VCEL |
|---|---|---|
| Founded | 1976 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | PRA | VCEL |
|---|---|---|
| Price | $24.05 | $37.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $22.50 | ★ $57.50 |
| AVG Volume (30 Days) | 405.2K | ★ 599.1K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | ★ 0.66 | 0.25 |
| Revenue | ★ $1,120,385,000.00 | $258,716,999.00 |
| Revenue This Year | N/A | $17.86 |
| Revenue Next Year | $1.24 | $18.55 |
| P/E Ratio | ★ $36.59 | $152.71 |
| Revenue Growth | N/A | ★ 14.05 |
| 52 Week Low | $13.90 | $29.24 |
| 52 Week High | $24.41 | $63.00 |
| Indicator | PRA | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 50.86 |
| Support Level | $24.14 | $35.53 |
| Resistance Level | $24.16 | $38.15 |
| Average True Range (ATR) | 0.10 | 1.31 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 31.31 | 69.31 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.